𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The Fine Tuning of Therapy for Chronic Myeloid Leukemia and Upcoming Challenges

✍ Scribed by Talpaz, Moshe

Book ID
119936056
Publisher
CIG Media Group, LP.
Year
2008
Tongue
English
Weight
55 KB
Volume
8
Category
Article
ISSN
1557-9190

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Acute myeloid leukemia developing during
Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities
✍ Attaphol Pawarode; Sheila N.J. Sait; Alain Nganga; Lionel J. Coignet; Maurice Ba πŸ“‚ Article πŸ“… 2007 πŸ› Elsevier Science 🌐 English βš– 171 KB

The BCR/ABL tyrosine kinase inhibitor imatinib mesylate produces a high rate of cytogenetic responses in patients with Philadelphia (Ph)-positive chronic myeloid leukemia (CML), but secondary clonal chromosome abnormalities may develop in Ph-negative cells, and acute myeloid leukemia (AML) has been

Has the time come for induction and main
Has the time come for induction and maintenance imatinib therapy in chronic myeloid leukemia?
✍ Edgar Faber πŸ“‚ Article πŸ“… 2009 πŸ› Elsevier Science 🌐 English βš– 90 KB

Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML) and there is no doubt about its role in the first-line therapy of this myeloproliferation. However, there is continuing discussion about how to dose it. Routinely, avoiding single doses lower than 300 mg and continuous daily